Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Bright Minds Biosciences Inc. has 12 disclosed suppliers and 0 disclosed customers. Each one is named in an SEC filing, either Bright Minds Biosciences Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a customer of Bright Minds Biosciences Inc.. Customers appear here when Bright Minds Biosciences Inc. names them, or when a company names Bright Minds Biosciences Inc. as a supplier in its own annual report.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Pursuant to the terms and conditions of the Exclusive License Agreement, UIC granted the Company an exclusive license to the Inventions (the " License ").”
FILING20-F0001062993-24-021301cik 0001827401
“The Company leases its executive headquarters located at 19 Vestry St., New York, NY 10013 pursuant to a lease agreement (the " Vestry Lease Agreement ")between the Company and Gerep Realty Corp., as landlord, dated August 13, 2021, as amended on May 31, 2022.”
FILING20-F0001062993-24-021301cik 0001827401
“The Company leases laboratory space located at Technology Innovation Center, 10437 W Innovation Dr, Wauwatosa, WI 53226 pursuant to a commercial laboratory lease dated May 10, 2021, as amended as of November 17, 2021, May 27, 2022, January 3, 2023, May 9, 2023, and May 6, 2024 (the " Wisconsin Lease ") between the Company and Technology Innovation Center LLC.”
FILING20-F0001062993-24-021301cik 0001827401
“The Company leases office space located at Portal Innovations, 400 N. Aberdeen St., Suite 900, Chicago, IL 60647 pursuant to a Chicago membership agreement (the " Chicago Agreement ") between the Company and ZoE Life Fulton Labs Incubator, LLC, with an initial date of November 28, 2023, as extended on December 3, 2024.”
FILING20-F0001062993-24-021301cik 0001827401
“Opioid withdrawal (Opioid use disorder, OUD) Substance use Disorder in rats (Dr. Cunningham lab) Determine the efficacy of test compound to suppress drug intake in male rats trained to stably self-administer fentanyl Rats treated with test compound (in higher doses) experienced 65% less fentanyl intake in an opioid use rat model”
FILING20-F0001062993-24-021301cik 0001827401
“Safety Screen 44, hERG screening and Ames test at Eurofins (both 2A and 2A/2C programs)”
FILING20-F0001062993-24-021301cik 0001827401
“Head Twitch Response trials (Halberstadt lab) (both 2A and 2A/2C programs) Evaluate head twitch response in mice 16 BMB compounds screened with a range of activity in vivo. The most active compounds are selected for a further assessment in ADMEPK studies”
FILING20-F0001062993-24-021301cik 0001827401
“Epilepsy NIH ETSP program (collaboration on epilepsy).”
FILING20-F0001062993-24-021301cik 0001827401
“Pain Preclinical Screening Platform for Pain (PSPP) - NIH collaboration (plantar incision and L5/L6 nerve ligation rat models) In vitro opioid & abuse liability, PK and protein binding studies Assess effects in animal pain models The test compound has passed the Tier 1 and is in process of Tier 2 studies BMB-201 significantly reduced mechanical allodynia, but not guarding behavior, in a dose-dependent manner. In female rats, 30 mg/kg of A39a significantly reduced both mechanical allodynia and guarding behavior compared to vehicle-treated rats of the same sex. 10 mg/kg also had a modest effect on guarding behavior in females.”
FILING20-F0001062993-24-021301cik 0001827401
“PsychoGenics Inc. collaboration (SmartCube model) To assess the potential of compounds to treat psychiatric disorders by comparing their complex behavioral profiles with those from a proprietary reference database at the drug class level BMB compounds showed clear antidepressant class profile in SmartCube model”
FILING20-F0001062993-24-021301cik 0001827401
“Alzheimer's Disease Dave Morgan Test the compound for behavioral changes in APP+PS1 mice (model of Alzheimer's Disease) Test compound showed significant effect in agitation in open field without other effects on learning and memory performance”
FILING20-F0001062993-24-021301cik 0001827401
“Lead optimization - BRET (Bioluminescence Resonance Energy Transfer) assays (John McCorvy) Describe the 5-HT2 profile of the test compounds Choose lead and backup compounds More than 100 compounds screened and profiled Lead and backup compounds with minimal 2B agonism are selected”
FILING20-F0001062993-24-021301cik 0001827401
Watchlist prices, news filtered to it, and its next report on your desk.
DRUG (Bright Minds Biosciences Inc.) has 12 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Bright Minds Biosciences Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 59.90 · gapped above the open, then crossed back over prior close. High/low 61.00 at 10:30 am ET, 59.90 at 4:00 pm ET.